A Look at the Upcoming Multiple Sclerosis Medicines
There are three oral drugs that should come out first for Multiple Sclerosis. While these MS drugs will be a welcome alternative to the injectibles currently available to treat Multiple Sclerosis, we are still a ways away from a cure for MS.
Fingolimod - FTY720
- oral
- in phase III trials
- reduces relapse rate by over 50%
- 2% of patients showed serious adverse side effects including heart and liver problems
- may repair or reduce damage
Cladribine
- oral
- reduces brain lesions and disability progression
- reduces relapse rate by just under 60%
- side effects reducing white blood cells (which increases infection susceptibility) and higher incidence of cancer
Fampridine-SR
- oral, similar in function to 4ap
- improves walking ability
- well-tolerated with few side effects
It is very exciting that so many (over 10) are on the near horizon for treating multiple sclerosis. It is unfortunate that the first three that should be released don't do all that much more than current disease-modifying MS drugs -- other than the fact that they are oral (which is always good).
Labels: cladribine, fampridine, fingolimod, MS, multiple sclerosis
